[Palivizumab and bronchiolitis: need to apply the efficiency in order to join clinical practice to scientific studies].
González de Dios
Javier
J
Ochoa Sangrador
Carlos
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D035843:Biomedical Research; D001988:Bronchiolitis / Q000188:drug therapy* / Q000821:virology; D015510:Clinical Medicine; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab